Post-Stroke Spasticity with Contractures
The condition you're describing is post-stroke spasticity with secondary muscle contractures, which affects approximately 50% of stroke survivors within six months and up to 90% in clinically targeted muscles within one year 1, 2.
Understanding the Condition
This is not a single named syndrome but rather a common complication of stroke characterized by:
- Spasticity: Abnormal velocity-dependent increases in muscle tone and exaggerated reflexes that develop after upper motor neuron damage 3
- Contractures: Fixed shortening of muscles and soft tissues that restricts passive range of motion 1
- Weakness: Loss of voluntary motor control from corticospinal tract damage 4
The lower extremities are commonly affected, with plantar flexors (gastrocnemius, soleus), hamstrings, rectus femoris, and gluteus maximus showing 16.6-20.1% shortening 1. This often manifests as an equinovarus deformity (foot turned inward and downward) that impairs gait, increases fall risk, and causes pain and skin breakdown 5.
Key Clinical Features
Contractures develop early and frequently:
- 52% of stroke patients develop at least one contracture within 6 months 2
- The earliest contractures can appear as early as 2 months post-stroke 6
- In specialized spasticity clinics, 90.9% of selected muscles show contractures within one year 1
Important distinction: Hypertonia (increased resistance to passive stretch) is more closely associated with contracture than reflex hyperexcitability 6. Many patients with contractures do not actually have increased tonic stretch reflexes—the contracture itself may potentiate spasticity rather than the reverse 6.
Predictive Factors
Muscle weakness is the most significant predictor of contracture development in the elbow, wrist, and ankle, though prediction models explain only 6-20% of variance 2. Other predictors include:
- Age (older patients at higher risk) 1, 7
- Severity of initial arm paresis 7
- Presence of aphasia and facial palsy at index stroke 7
Notably, spasticity severity correlates with contracture severity, but disease duration does not 1, suggesting early intervention is critical.
Clinical Implications
This combination of spasticity, contractures, and weakness creates a cascade of functional problems:
- Gait instability and increased fall risk (twice the hip fracture risk compared to non-stroke fallers) 8
- Difficulty with bracing and orthotics 5
- Pain and pressure ulceration 5
- Reduced independence in activities of daily living 8
Critical pitfall: Don't assume spasticity is the primary driver of disability. The "negative" features (weakness and loss of dexterity) typically cause more functional limitation than spasticity itself 6. However, spasticity can interfere with function and paradoxically may also assist with functional mobility tasks in some patients 3.
Management Framework
Treatment should target both spasticity and contracture prevention:
For focal spasticity (affecting specific muscle groups):
- Botulinum toxin injection is recommended for both upper and lower limb spasticity to reduce tone, improve range of motion, and enhance function 8. The 2024 VA/DoD guidelines downgraded this from "strong for" to "weak for" based on evidence showing similar efficacy to oral baclofen except for ankle spasticity 3
For generalized spasticity:
- Oral antispasticity agents (e.g., baclofen 30-80 mg/day) are useful but may cause dose-limiting sedation 3, 8
- Intrathecal baclofen may be considered for severe cases refractory to other treatments, as early as 3-6 months post-stroke 8
Adjunctive therapies:
- Functional electrical stimulation, neuromuscular electrical stimulation, or transcutaneous electrical nerve stimulation for motor outcomes 3
- Physical modalities may temporarily improve spasticity as adjuncts to rehabilitation 8
Avoid: Splints and taping are not recommended for prevention of wrist and finger spasticity 8.